BCDA - צמיחת מכירות משנה לשנה (TTM) biocardia.com

BioCardia, Inc. (BCDA) management is focused on developing cell-based therapies for heart failure. The LTM sales growth YoY serves as a stability indicator, where the -100.00 mark reflects the latest data. Risks are linked to single-product dependency and financial pressure; however, patent protection for myocardial delivery systems and stringent FDA requirements create a significant moat for the business.

For BioCardia, Inc. (BCDA), a leader in intracardiac delivery of cell therapy, this indicator determines the scaling speed of the commercial success of innovative myocardial restoration systems. By analyzing the year-over-year (TTM) operating revenue dynamics on the GURU.Markets platform, an investor can observe the smoothed revenue growth rate over a rolling year, where extreme values signal either an expansion phase or the risk of an imminent slowdown in fundamental growth.